Antimicrobial susceptibility of Clostridium difficile isolated from food animals on farms

International Journal of Food Microbiology

Volumn 227, Issue , 2016, Pages 1-5

  Thitaram, S N ^a   Frank, J F ^b   Siragusa, G R ^a,d   Bailey, J S ^a,e   Dargatz, D A ^c   Lombard, J E ^c   Haley, C A ^c   Lyon, S A ^a,f   Fedorka Cray, P J ^a,g  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b UNIVERSITY OF GEORGIA   (United States)

^c CENTERS FOR EPIDEMIOLOGY AND ANIMAL HEALTH   (United States)

^d Eurofins Medinet Inc   (Germany)

^e Bio Mérieux Inc   (United States)

^f Chick fil A Inc   (United States)

^g NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Antimicrobial susceptibility; Beef cattle; Clostridium difficile; Dairy cattle; Swine

Indexed keywords

AMOXICILLIN; AMPICILLIN; ANTIBIOTIC AGENT; CLAVULANIC ACID; CLINDAMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; METRONIDAZOLE; RIFAMPICIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANIMAL FOOD; ANIMAL HEALTH; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BEEF CATTLE; DAIRY CATTLE; EPSILOMETER TEST; FARM ANIMAL; MIC90; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; PIG; AGRICULTURAL LAND; ANIMAL; BOVINE; CLASSIFICATION; DRUG EFFECTS; FECES; HUMAN; ISOLATION AND PURIFICATION; MEAT; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; SWEDEN;

ANIMALS; ANTI-BACTERIAL AGENTS; CATTLE; CLOSTRIDIUM DIFFICILE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FARMS; FECES; HUMANS; MEAT; MICROBIAL SENSITIVITY TESTS; SWEDEN; SWINE;

EID: 84962314901     PISSN: 01681605     EISSN: 18793460     Source Type: Journal    
DOI: 10.1016/j.ijfoodmicro.2016.03.017     Document Type: Article

References (77)

1. Aspevall O., Lundberg A., Burman L.G., Akerlund T., Svenungsson B. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR Ribotypes in a Swedish university hospital. Antimicrob. Agents Chemother. 2006, 50:1890-1892.
2. Barbut F., Petit J.C. Epidemiology of Clostridium difficile-associated infections. Clin. Microbiol. Infect. 2001, 7:405-410.
3. Bartlett J.G. Antibiotic-associated diarrhea. Clin. Infect. dis. 1992, 15:573-581.
4. Bartlett J.G. The new epidemic of Clostridium difficile-associated enteric disease. Ann. Intern. Med. 2006, 145:758-764.
5. Bishara J., Bloch Y., Garty M., Behor J., Samra Z. Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn. Microbiol. Infect. dis. 2006, 54:141-144.
6. Bliss D., Johnson S., Savik K., Clabots C.R., Willard K., Gerding D.N. Acquisition of Clostridium difficile and Clostridium difficile-associated diarrhea in hospitalized patients receiving tube feeding. Ann. Intern. Med. 1998, 129:1012-1019.
7. Bourgault A.-M., Lamothe F., Loo V.G., Poirier L., the CDAD-CSI Study Group In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Quebec, Canada. Antimicrob. Agents Chemother. 2006, 50:3473-7475.
8. Brazier J.S. The epidemiology and typing of Clostridium difficile. J. Antimicrob. Chemother. 1998, 41:47-57.
9. Brazier J.S., Fawley W., Freeman J., Wilcox M.H. Reduced susceptibility of Clostridium difficile to metronidazole. J. Antimicrob. Chemother. 2001, 48:741-742.
10. Brook I. Pseudomembranous colitis. Anaerobic Infections Diagnosis and Management 2008, 325-330. Informa Healthcare USA, Inc., New York. I. Brook (Ed.).
11. Brown E., Talbot G.H., Axelrod P., Provencher M., Hoegg C. Risk factors for Clostridium difficile toxin-associated diarrhea. Infect. Control Hosp. Epidemiol. 1990, 11:283-290.
12. Cartmill T.D.I., Panigrahi H., Worsley M.A., McCann D.C., Nice C.N., Keith E. Management and control of a large outbreak of diarrhea due to Clostridium difficile. J. Hosp. Infect. 1994, 27:1-15.
13. Chang T.W. Antibiotic-associated injury to the gut. Bockus Gastroenterology 1985, 2583-2592. WB Saunders, Philadelphia, PA. J.E. Berk (Ed.).
14. CLSI Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard 2012, Clinical and Laboratory Standards Institute, Wayne, PA, Document M11 A8. eighth ed.
15. Drudy D., Harnedy N., Fanning S., Hannan M., Kyne L. Emergence and control of fluoroquinolone-resistant, toxin A-negative, toxin-B positive Clostridium difficile. Infect. Control Hosp. Epidemiol. 2007, 28:932-940.
16. Drummond L.J., McCoubrey J., Smith D.G., Starr G., Poxton J.M. Changes in sensitivity patterns to selected antibiotics in Clostridium difficile in geriatric in-patients over an 18-month period. J. Med. Microbiol. 2003, 52:259-263.
17. Fedorka-Cray P.J., Englen M.D., Gray J.T., Hudson C., Headrick M.L. Programs for monitoring antimicrobial resistance. Anim. Biotechnol. 2002, 13:43-55.
18. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile associated diarrhea and colitis, American College of Gastroenterology, Practice Parameter Committee. Am. J. Gastroenterol. 1997, 92:739-750.
19. Fekety R., Shah A.B. Diagnosis and treatment of Clostridium difficile colitis. J. Am. Med. Assoc. 1993, 269:255-257.
20. Ferreira C.E.A., Nakano V., Avila-Campos M.J. Cytotoxicity and antimicrobial susceptibility of Clostridium difficile isolated from hospitalized children with acute diarrhea. Anaerobe 2004, 10:171-177.
21. Freeman J., Wilcox M.H. Antibiotics and Clostridium difficile. Microbes Infect. 1999, 1:377-384.
22. Garey K.W., Dao-Tran T.K., Jiang Z.D., Price M.P., Gentry L.O., DuPont H.L. A clinical risk index for Clostridium difficile infection in hospitalized patients receiving broad-spectrum antibiotics. J. Hosp. Infect. 2008, 70:142-147.
23. George W.L., Sutter V.L., Finegold S.M. Antimicrobial agent-induced diarrhea-a bacterial disease. J. Infect. dis. 1977, 136:822-828.
24. George R.H., Symonds J.M., Dimock F., Brown J.D., Arubi Y., Shinagawa N., Keighley M.R., Alexander-Williams J., Burdon D.W. Identification of Clostridium difficile as a cause of pseudomembranous colitis. Br. Med. J. 1978, 1:695.
25. Gerding D.N. Disease associated with Clostridium difficile infection. Ann. Intern. Med. 1989, 110:255-257.
26. Gerding D.N., Johnson S., Peterson L.R., Mulligan M.E., Silva J. Clostridium difficile-associated diarrhea and colitis. Infect. Control Hosp. Epidemiol. 1995, 16:459-477.
27. Gorbach S.L. Antibiotics and Clostridium difficile. N. Engl. J. Med. 1999, 341:1690-1692.
28. Groschell D.H. Clostridium difficile infection. Crit. Rev. Clin. Lab. Sci. 1996, 33:203-245.
29. Hecht D.W. Anaerobes: antibiotic resistance, clinical significance, and the role of susceptibility testing. Anaerobe 2006, 12:115-121.
30. Hecht D.W., Galang M.A., Sambol S.P., Osmolski J.R., Johnson S., Gerding D.N. In vitro activities of 15 antimicrobials agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983-2004. Antimicrob. Agents Chemother. 2007, 51:2716-2719.
31. Indra A., Schmid D., Huhulescu S., Hell M., Gattringer R., Hasenberger P., Fiedler A., Wewalka G., Allerberger F. Characterization of clinical Clostridium difficile isolates by PCR ribotyping and detection of toxin genes in Austria, 2006-2007. J. Med. Microbiol. 2008, 57:702-708.
32. Jamal W.Y., Mokaddas M., Verghese T.L., Rotimi V.O. In vitro activity of 15 antimicrobial agents clinical isolates of Clostridium difficile in Kuwait. Int. J. Antimicrob. Agents 2002, 20:270-274.
33. John R., Brazier J.S. Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J. Hosp. Infect. 2005, 61:11-14.
34. Johnson S., Samore M.H., Farrow K.A. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N. Engl. J. Med. 1999, 341:1645-1651.
35. Johnson S., Samore M.H., Farrow K.A., Killgore G.E., Tenover F.C., Jyras D., Rood J.I., DeGirolami P., Baltch A.L., Rafferty M.E., Pear S.M., Gerding D.N. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N. Engl. J. Med. 1999, 341:1645-1651.
36. Johnson S., Schriever C., Galang M., Kelly C.P., Gerding D.N. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. dis. 2007, 44:846-848.
37. Kelly C.P., Pothoulakis C., LaMont J.T. Clostridium difficile colitis. N. Engl. J. Med. 1994, 330:257-262.
38. Kikuchi E., Miyamoto Y., Narushima S., Iton K. Design of species-specific primers to identify 13 species of Clostridium harbored in human intestinal tracts. Microbiol. Immunol. 2002, 46:353-358.
39. Kink J.A., Williams J.A. Antibodies to recombinant Clostridium difficile toxins A and B are effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect. Immun. 1998, 66:2018-2025.
40. Kuijper E.J., Surawicz C.M. Clostridium difficile infection. Lancet 2008, 371:1486-1488.
41. Kyne L., Warny M., Qamar A., Kelly C.P. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N. Engl. J. Med. 2000, 342:390-397.
42. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin. Infect. dis. 2002, 34:482-492.
43. Letournel-Glomaud C., Houssaye S., Milhaiha L., Ghnassia J.C. E-test antibiotics susceptibility of strict anaerobic bacteria. Anaerobe 2003, 9:281-284.
44. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., Bourgault A.M., Nguyen T., Frenette C., Kelly M., Vibien A., Brassard P., Fenn S., Dewar K., Hudson T.J., Horn R., Rene P., Monczak Y., Dascal A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N. Engl. J. Med. 2005, 353:2442-2449.
45. Martin H., Willey B., Low D.E., Staempfli H.R., McGeer A., Boerlin P., Mulvey M., Weese J.S. Characterization of Clostridium difficile strains isolated from patients In Ontario, Canada, from 2004-2006. J. Clin. Microbiol. 2008, 46:2999-3004.
46. McCusker M.E., Harris A.D., Perencevich E., Roghmann M.-C. Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg. Infect. dis. 2003, 9:730-733.
47. McFarland L.V., Elmer G.W., Suravicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am. J. Gastroenterol. 2002, 97:1769-1775.
48. Nelson D.E., Auerbach S.B., Baltch A.L., Desjarardin E., Beck-Sague C., Rheal C., Smith R.P., Jarvis W.R. Epidemic Clostridium difficile-associated diarrhea: role of second- and third-generation cephalosporins. Infect. Control Hosp. Epidemiol. 1994, 15:88-94.
49. O'Conner J.R., Galang M.A., Sambol S.P., Hecht D.W., Vedantam G., Gerding D.N., Johnson S. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob. Agents Chemother. 2008, 52:2813-2817.
50. Olson M.M., Shanholtzer C.J., Lee, Gerding D.N. Ten years of prospective Clostridium difficile associated-disease surveillance and treatment at the Minneapolis VA medical center, 1982-1991. Infect. Control Hosp. Epidemiol. 1994, 15:371-381.
51. Olsson-Liljequist B., Nord C.E. Methods for susceptibility testing of anaerobic bacteria. Clin. Infect. dis. 1994, 18(Supplement 4):S293-S296.
52. Owens R.C., Donskey C.J., Gaynes R.P., Loo V.G., Muto C.A. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin. Infect. dis. 2008, 46(Supplement 1):S19-S31.
53. Pelaez T., Alcala L., Alonso R., Martin-Lopez A., Garcia-Arias V., Marin M., Bouza E. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob. Agents Chemother. 2005, 49:1157-1159.
54. Pepin J., Saheb N., Coulombe M.A., Alary M.E., Corriveau M.P., Authier S., Lebranc M., Rivard G., Bettez M., Primeau V., Nguyen M., Jacob C.E., Lanthier L. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin. Infect. dis. 2005, 41:1254-1260.
55. Pituch H., Obuch-Woszczatynski P., Wultanska D., Meisel-Mikolajczyk F., Luczak M. A survey of metronidazole and vancomycin resistance in strains of Clostridium difficile isolated in Warsaw, Poland. Anaerobe 2005, 11:197-199.
56. Poilane I., Cruaud P., Torlotin J.C., Collignon A. Comparison of the etest to the reference agar dilution method for antibiotic susceptibility testing of Clostridium difficile. Clin. Microbiol. Infect. 2000, 6:154-156.
57. Rattanaumpawan P., Morales K.H., Binkley S., Synnestvedt M., Weiner M.G., Gasnik L.B., Fishman N.O., Lautenbach E. Cumulative incidence of and risk factors for unnecessary use of double anaerobic coverage therapy. SHEA 2011 Annual Scientific Meeting, April 1-4, Dallas, TX 2011, (Abstract 374).
58. Rodriguez-Palacios A., Stampfli H.R., Duffield T., Peregrine A.S., Trotz-Williams L.A., Arroyo L.G., Brazier J.S., Weese J.S. Clostridium difficile PCR ribotypes in calves, Canada. Emerg. Infect. dis. 2006, 12:1730-1736.
59. Rodriguez-Palacios A., Stampfli H.R., Duffield T., Weese J.S. Clostridium difficile in retail ground meat, Canada. Emerg. Infect. dis. 2007, 13:485-487.
60. Rosenblatt J.E., Gustafson D.R. Evaluation of the Etest for susceptibility testing of anaerobic bacteria. Diagn. Microbiol. Infect. dis. 1995, 22:279-284.
61. Rupnik M. Is Clostridium difficile-associated infection a potentially zoonotic and foodborne disease?. Clin. Microbiol. Infect. 2007, 13:457-459.
62. Simango C. Prevalence of Clostridium difficile in the environment in a rural community in Zimbabwe. Trans. R. Soc. Trop. Med. Hyg. 2006, 100:1146-1150.
63. Simango C., Mwakurudza S. Clostridium difficile in broiler chickens sold at market in Zimbabwe and their antimicrobial susceptibility. Int. J. Food Microbiol. 2008, 124:268-270.
64. Songer J.G., Anderson M.A. Clostridium difficile: an important pathogen of food animals. Anaerobe 2006, 12:1-4.
65. Songer J.G., Post K.W., Larson D.J., Jost B.H., Glock R.D. Infection of neonatal swine with Clostridium difficile. J. Swine Health Prod. 2000, 8:185-189.
66. Spencer R.C. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J. Antimicrob. Chemother. 1998, 41(Supplement C):21-27.
67. Spigaglia P., Barbanti F., Mastrantonio P., Brazier J.S., Barbut F., Delmee M., Kuijper E., Poxton R. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J. Med. Microbiol. 2008, 57:784-789.
68. Thitaram S.N., Frank J.F., Lyon S.A., Siragusa G.R., Bailey J.S., Lombard J.E., Haley C.A., Wagner B.A., Dargatz D.A., Fedorka-Cray P.J. Clostridium difficile from healthy animals: optimized isolation and prevalence. J. Food Prot. 2011, 74(1):130-133.
69. Tollefson L., Angulo F.J., Fedorka-Cray P.J. National surveillance for antibiotic resistance in zoonotic enteric pathogens. veterinary clinics of North America. Food Anim. Pract. 1998, 14:141-150.
70. Tollefson L., Fedorka-Cray P.J., Angulo F.J. Public health aspects of antibiotic resistance monitoring in the USA. Acta Vet. Scand. 1999, 92:67-75.
71. Voth D.E., Ballard J.D. Clostridium difficile toxins: mechanism of action and role in disease. Clin. Microbiol. Rev. 2005, 18:247-263.
72. Wong S.S.-Y., Woo P.C.-Y., Luk W.-K., Yuen K.-Y. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and etest. Diagn. Microbiol. Infect. dis. 1999, 34:1-6.
73. Worsley M.A. Infection control and prevention of Clostridium difficile infection. J. Antimicrob. Chemother. 1998, 41(Supplement C):59-66.
74. Wust J., Hardegger U. Comparison of the Etest and a reference dilution method for susceptibility testing of anaerobic bacteria. Eur. J. Clin. Microbiol. Infect. dis. 1992, 11:1169-1173.
75. Zar F.A., Bakkanagari S.R., Moorthi K.M., Davis M.B. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin. Infect. dis. 2007, 45:302-307.
76. Zheng L., Citron D.M., Genheimer C.W., Sigmon S.F., Carman R.J., Lyerly M., Goldstein J.C. Molecular characterization and antimicrobial susceptibilities of extra intestinal Clostridium difficile isolates. Anaerobe 2007, 13:114-120.
77. Zwiener R.J., Belknap W.M., Quan R. Severe pseudomembranous enterocolitis in a child: case report and literature review. Pediatr. Infect. dis. J. 1989, 8:876-882.